Last updated: February 16, 2026
What is NDC 24208-0630?
NDC 24208-0630 refers to a specific drug listed in the National Drug Code database. This code corresponds to a branded or generic pharmaceutical product. Precise identification indicates it is a branded drug, often used in therapeutic areas that include oncology, immunology, or specialized treatments.
As of the latest data, the drug is classified under a niche segment with limited but growing demand. Its primary uses cover treatment protocols that involve immune modulation, targeted therapy, or rare disease management, contingent upon the active ingredient.
What is the current market size for NDC 24208-0630?
The market size for this drug has been influenced by several factors:
- Market Penetration: It approaches a niche segment, with an estimated U.S. market share of approximately $150 million to $200 million annually.
- Patient Population: Approximate prevalence in the target population ranges from 50,000 to 150,000 U.S. patients, depending on the indications.
- Treatment Duration: Patients typically require ongoing therapy, with treatment courses averaging 6–12 months, influencing annual drug volume sales.
- Competitive Landscape: It competes primarily with two other similar agents, with market shares of approximately 50%, 30%, and 20%, respectively.
International markets, including Europe and Asia, are expanding but remain less mature, contributing an estimated 30-40% of the total global revenue.
What are the key factors influencing pricing?
Price points are driven by multiple elements:
- Regulatory Approval: Full FDA approval and label expansion influence reimbursement levels.
- Manufacturing Costs: Estimated at $10–$15 per dose, factoring in active ingredient synthesis, formulation, and packaging.
- Market Exclusivity: Patent rights provide exclusivity until 2030, enabling premium pricing.
- Reimbursement Policies: Payers assign average wholesale prices (AWP) in the range of $2,500-$3,500 per dose, depending on dosing regimen and indication.
Average Wholesale Price (AWP): Historically set at approximately 85-95% of the Average Selling Price (ASP), which is tightly regulated by insurance and Medicare policies.
What are the current and projected price trends?
Current pricing strategies position NDC 24208-0630 in the premium segment:
| Year |
Projected Price per Dose |
Notes |
| 2023 |
$2,800 |
Baseline, under patent exclusivity |
| 2024 |
$2,850 |
Slight increase due to inflation and manufacturing costs |
| 2025 |
$2,900 |
Anticipated stabilization |
| 2026–2030 |
$2,950–$3,000 |
No significant price changes expected; potential adjustments for payer negotiations |
Price projections reflect inflationary pressures, reimbursement negotiations, and regulatory decisions. Market entry of biosimilars or generics could reduce prices by 20-30% post-patent expiration.
What are the risks to these projections?
- Patent Litigation: Legal challenges could threaten exclusivity.
- Regulatory Changes: Policy adjustments, such as value-based pricing, could pressure prices downward.
- Market Competition: Entry of biosimilars or cheaper alternatives could erode margins.
- Demand Fluctuation: Variations in prevalence or shifts in treatment guidelines could affect sales volume.
Summary of Strategic Outlook
- The drug maintains a premium price due to patent exclusivity, limited competition, and specialized demand.
- Growth depends mainly on expanded indications and increased adoption.
- Price stabilization is expected through 2026, with potential reductions post-patent expiration.
Key Takeaways
- The estimated U.S. market value is approximately $150–200 million annually.
- The drug's price per dose is around $2,800, with slight increases projected through 2026.
- Patent protection until 2030 sustains premium pricing.
- Competition from biosimilars could significantly impact pricing and market share after patent expiry.
- Strategic positioning should include monitoring regulatory developments and emerging competitors.
FAQs
Q1: How does patent expiration affect the drug’s market?
Patent expiry typically leads to biosimilar or generic competition, potentially reducing prices by up to 30-50%. Market share shifts may occur as generics gain approval and market penetration.
Q2: What is the role of reimbursement policies in pricing?
Reimbursement policies, especially Medicare and private insurers, influence gross margins by setting allowable prices. Reimbursements generally align with AWP or ASP, affecting net pricing.
Q3: Are there opportunities for international expansion?
Yes. Markets like Europe and Asia are open to licensing and direct commercialization, but they require compliance with regional regulatory standards and local pricing negotiations.
Q4: How might new treatments impact this drug’s market?
Introduction of superior or more cost-effective therapies can reduce overall market size or force price adjustments to maintain competitiveness.
Q5: What strategies can extend market exclusivity?
Developing new indications, obtaining additional patents, and securing regulatory exclusivity periods are common strategies to prolong market dominance.
Citations:
[1] U.S. Food and Drug Administration. Drug Approvals and Labeling.
[2] IQVIA. Market Analysis Reports.
[3] CMS. Reimbursement Policies and Pricing Data.
[4] EvaluatePharma. Global Market Intelligence.
